Quantcast

Latest Juvenile myelomonocytic leukemia Stories

2014-01-08 12:28:20

NEW YORK, Jan. 8, 2014 /PRNewswire/ -- Bone marrow transplants are a $1.3 billion market and the fastest-growing hospital procedure in the U.S. They are the only potential cure for many blood cancers such as acute myeloid leukemia (AML) in older patients. The procedure is technically called hematopoietic stem cell transplantation (HSCT) and can be either a bone marrow transplant (BMT) or transplant of blood stem cells isolated from peripheral blood (PBSC). In either case, it involves...

2013-12-09 14:08:58

Bortezomib (Velcade) reduces GVHD, boosts survival Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute. In a new phase 2 trial, patients treated with bortezomib had lower rates of severe acute GVHD and treatment-related mortality, and experienced better one-year overall...

2013-12-09 10:45:08

Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according to a study from Dana-Farber Cancer Institute presented at the annual meeting of the American Society of Hematology. "This is good evidence that age alone should not limit who should get a transplant for MDS," said Gregory Abel, MD, MPH, a medical oncologist at Dana-Farber. "Calendar age is less important than other measures,...

2013-12-09 10:43:09

Hematopoietic stem cell transplantation (HSCT), once considered an effective yet risky alternative to drug therapy for blood cancer, has become more accessible and successful in a wide range of patients as a result of major advances in transplant strategies and technologies. Several studies representing these advances were presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans. HSCT is effectively used today as a form of "replacement"...

2013-12-09 10:11:07

8 of 9 children treated doing well, according to data presented to American Society of Hematology Hematopoietic stem cell transplantation (HSCT), once considered an effective yet risky alternative to drug therapy for blood cancer, has become more accessible and successful in a wide range of patients as a result of major advances in transplant strategies and technologies. Several studies representing these advances were presented today during the 55th American Society of Hematology Annual...

2012-12-11 12:00:01

Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston. The trial leaders will present the results of the Dana-Farber Cancer Institute ALL Consortium study, which involved nearly 500 patients under age 18 with B-precursor acute...

2012-05-19 23:02:42

Gold Rush Cure Foundation expresses praise for Health Canada's decision to approve the stem cell therapy Prochymal for the treatment of Graft-versus-host disease in children. Laguna Niguel, California (PRWEB) May 19, 2012 The Gold Rush Cure Foundation, a 501 (c)(3) non-profit organization dedicated to raising public awareness and funding for research to eradicate childhood cancer, today expressed praise for Health Canada´s decision to approve the stem cell therapy Prochymal®...

2012-05-09 21:35:10

Study is first to show feasibility and efficacy of a new use for autologous stem cell transplant For the first time, scientists at Fred Hutchinson Cancer Research Center have transplanted brain cancer patients' own gene-modified blood stem cells in order to protect their bone marrow against the toxic side effects of chemotherapy. Initial results of the ongoing, small clinical trial of three patients with glioblastoma showed that two patients survived longer than predicted if they had not...

2012-04-07 23:00:52

A revolutionary physician-friendly integrated clinical information solution. Omaha, NE (PRWEB) April 07, 2012 OTTR Chronic Care Solutions, an Omaha-based clinical process management and informatics company, recently announced the launch of its new OTTRbmt — Bone Marrow Stem Cell Transplant (BMT) Patient Management System. According to CEO Lou Halperin, “This enhancement to our OTTR - Transplant Enterprise Suite is the next step in OTTR Chronic Care Solutions´ commitment to...

2011-12-13 01:08:02

Patients who receive a blood stem cell transplant from a donor outside of their family to treat leukemia and other blood diseases are more likely to have graft failure but less likely to experience graft-versus-host disease, a condition caused by the donor cells attacking the recipient's body, if the transplanted blood cells come directly from a donor's bone marrow, rather than from blood stem cells circulating in the donor's bloodstream (PBSCs), according to new research. Although the study...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.